- Home
- IBRX vs KNTK Comparison
IBRX vs KNTK Comparison
Compare IBRX & KNTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- KNTK
- Stock Information
- Founded
- IBRX 2014
- KNTK 2017
- Country
- IBRX United States
- KNTK United States
- Employees
- IBRX N/A
- KNTK N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- KNTK Natural Gas Distribution
- Sector
- IBRX Health Care
- KNTK Utilities
- Exchange
- IBRX Nasdaq
- KNTK Nasdaq
- Market Cap
- IBRX 2.3B
- KNTK 2.7B
- IPO Year
- IBRX N/A
- KNTK N/A
- Fundamental
- Price
- IBRX $2.81
- KNTK $41.42
- Analyst Decision
- IBRX Strong Buy
- KNTK Buy
- Analyst Count
- IBRX 5
- KNTK 9
- Target Price
- IBRX $11.40
- KNTK $56.56
- AVG Volume (30 Days)
- IBRX 7.3M
- KNTK 1.2M
- Earning Date
- IBRX 08-11-2025
- KNTK 08-06-2025
- Dividend Yield
- IBRX N/A
- KNTK 7.53%
- EPS Growth
- IBRX N/A
- KNTK N/A
- EPS
- IBRX N/A
- KNTK 0.94
- Revenue
- IBRX $31,222,000.00
- KNTK $1,584,798,000.00
- Revenue This Year
- IBRX $567.98
- KNTK $15.38
- Revenue Next Year
- IBRX $160.56
- KNTK $34.42
- P/E Ratio
- IBRX N/A
- KNTK $43.90
- Revenue Growth
- IBRX 10238.41
- KNTK 20.36
- 52 Week Low
- IBRX $1.83
- KNTK $37.85
- 52 Week High
- IBRX $7.48
- KNTK $67.60
- Technical
- Relative Strength Index (RSI)
- IBRX 51.33
- KNTK 39.01
- Support Level
- IBRX $2.68
- KNTK $42.06
- Resistance Level
- IBRX $3.00
- KNTK $43.15
- Average True Range (ATR)
- IBRX 0.16
- KNTK 1.29
- MACD
- IBRX -0.00
- KNTK -0.17
- Stochastic Oscillator
- IBRX 62.00
- KNTK 9.22
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About KNTK Kinetik Holdings Inc.
Kinetik Holdings Inc is a midstream operator that provides gathering and processing services to gas and oil producers as well as pipeline transportation. In addition to directly operating pipelines, Kinetik also holds ownership stakes in several pipelines. The company operates in two reportable segments which include The Midstream Logistics segment operates under three service offerings, 1) gas gathering and processing, 2) crude oil gathering, stabilization, and storage services, and 3) produced water gathering and disposal. The Pipeline Transportation segment consists of three EMI pipelines originating in the Permian Basin with various access points to the U.S. Gulf Coast, Kinetik NGL Pipelines, and Delaware Link Pipeline.